Recent News

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

April 25, 2025

Primary Outcome Measures Number of Patients who Experience Dose-Limiting Toxicity Number of patients who experience a treatment-related adverse event Objective response rate (ORR) Duration of response (DOR) Progression free survival…

Immunotherapy to Treat Pleural Mesothelioma

April 25, 2025

Malignant pleural mesothelioma is a rare and very aggressive cancer with a poor outlook. One cancer treatment has brought hope though. The treatment is known as immune checkpoint inhibitors. There…

Johnson & Johnson’s Talc Settlement Proposal Denied

April 18, 2025

A United States Bankruptcy Judge from the Southern District of Texas has denied Johnson & Johnson’s $10 billion baby powder settlement proposal. This is the third time J&J has tried…

Hemithoracic Arc Radiotherapy Post Pleural Decortication

April 11, 2025

Primary Outcome Measures Acute Radiation Toxicity late radiation toxicity Inclusion Criteria Evidence of metastatic disease. Underwent Pleural decortication. Able to provide informed consent. Exclusion Criteria Poor pulmonary function tests. Recurrent…

Asbestos Delays Wildfire Cleanup

April 11, 2025

Asbestos testing with certified asbestos consultants and other experts has been ongoing since two wildfires, Eaton and Palisades, blazed across California in 2025. More properties that were burned in the…

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)

April 4, 2025

Primary Outcome Measures Diagnostic Performance Secondary Outcome Measures Location biopsy Staging Patient Management Uptake Values Changes uptake parameters due to anticancer treatment Correlate immunohistochemistry Incidental findings Safety Evaluation FAPI-injection Overall…

CAR-T Cell Therapy for Mesothelioma

April 4, 2025

Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure. With the disease being rare, there are limited treatment options for the disease. This is especially true for…

Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE VariaTionS (MAGNETS)

March 28, 2025

Primary Outcome Measures the comparison of prevalence of germline mutations in MPM patients vs asbestos exposed healthy subjects Secondary Outcome Measures Secondary aim will be the comparison of overall survival…

Asbestos Tailings Could be Used to Help the Environment

March 28, 2025

An abandoned asbestos mine in Baie Verte, in Newfoundland, is expected to have a significant environmental remediation project. BAIE Minerals, a company that specializes in mineral upcycling, plans to transform…

Anti-Mesothelin TNaive/​SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

March 21, 2025

Primary Outcome Measures Establish the recommended phase 2 dose (RP2D) of TNhYP218 CAR T cells based on dose-limiting toxicity (DLT) of defined adverse events (AEs). Determine the preliminary objective response…